Prime Medicine (PRME) Gains from Investment Securities (2022 - 2025)

Prime Medicine has reported Gains from Investment Securities for 4 years, with the latest figure at -$83.3 million in Q4 2025.

• For the quarter ending Q4 2025, Gains from Investment Securities fell 138975.0% year-over-year to -$83.3 million; the trailing twelve-month figure through Mar 2026 stood at $1.5 million (up 103.2% YoY), and the FY2025 full-year result was $432000.0, up 189.26% from the prior year.
• Gains from Investment Securities for Q4 2025 stood at -$83.3 million, down from $85.3 million in the prior quarter.
• The five-year high for Gains from Investment Securities was $85.3 million in Q3 2025, with the low at -$83.3 million in Q4 2025.
• Historically, Gains from Investment Securities has averaged -$586285.7 across 4 years, with a median of -$244000.0 in 2022.
• Annual changes were most pronounced in 2024 — Gains from Investment Securities soared 2741.68% — and 2025, when it sank 138975.0%.
• Prime Medicine's Gains from Investment Securities stood at -$36.7 million in 2022, then soared by 108.14% to $3.0 million in 2023, then slumped by 97.99% to $60000.0 in 2024, then slumped by 138975.0% to -$83.3 million in 2025.
• The last three Gains from Investment Securities figures came in at -$83.3 million (Q4 2025), $85.3 million (Q3 2025), and -$505000.0 (Q2 2025), per Business Quant data.